# OnCo record myeloma-transplant-ineligible (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/myeloma-transplant-ineligible/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "myeloma-transplant-ineligible" ;
  schema:name "Newly diagnosed multiple myeloma, transplant-ineligible"@en ;
  schema:alternateName "Transplant-ineligible myeloma"@en, "TI NDMM"@en, "Myeloma in older or frail patients"@en, "Newly diagnosed myeloma not for transplant"@en ;
  schema:description "Most people with newly diagnosed myeloma are too old or frail for a stem cell transplant. Combining a CD38 antibody with lenalidomide and dexamethasone (MAIA) and, for the fitter, with bortezomib as well (IMROZ), now keeps the disease away for around five years in many and lengthens life."@en ;
  schema:url <https://onco.cc/cancers/myeloma-transplant-ineligible/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_myeloma> ;
  schema:citation <https://en.wikipedia.org/wiki/Multiple_myeloma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/geriatric-assessment/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:targets <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/proteasome/>, <https://onco.cc/targets/cereblon/> ;
  onco:terms <https://onco.cc/terms/vrd/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/terms/r-iss/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/proteasome-inhibitor/>, <https://onco.cc/terms/imid/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/>, <https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/> ;
  onco:pipeline <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/trials/cartitude-5/>, <https://onco.cc/trials/cepheus/> ;
  onco:standardOfCare <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/trials/imroz/>, <https://onco.cc/trials/cepheus/>, <https://onco.cc/terms/vrd/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/technologies/geriatric-assessment/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/terms/maintenance-therapy/> .